Literature DB >> 11110839

The deltaF508 mutation in the cystic fibrosis transmembrane conductance regulator alters control of essential fatty acid utilization in epithelial cells.

F N Bhura-Bandali1, M Suh, S F Man, M T Clandinin.   

Abstract

Essential fatty acid (EFA) incorporation into phospholipid is influenced by chloride channels, suggesting that the cystic fibrosis (CF) transmembrane conductance regulator (CFTR) may regulate aspects of EFA metabolism. The objective of this study was to determine whether the DeltaF508 mutation in the CFTR lowers 18:2(n-6) levels in phospholipid. Control cells, CF cells and CF cells transfected with the "normal" CFTR gene or the DeltaF508 CFTR gene were cultured for 3-5 d and used to determine [1-(14)C]18:2(n-6) incorporation into cell lipids. CF cells exhibited low 18:2(n-6) levels in phospholipid, reduced [1-(14)C]18:2(n-6) incorporation into phospholipid (50% of control) and greater [1-(14)C]18:2(n-6) incorporation into the triacylglycerol fraction (400% of control; P: < 0.05). Kinetic modeling of time course data for [1-(14)C]18:2(n-6) incorporation revealed a loss of metabolic control over the intracellular partitioning of 18:2(n-6) between phospholipid and triacylglycerol pools in CF cells. Expression of the normal CFTR gene in transfected CF cells increased chloride efflux and the incorporation of [1-(14)C]18:2(n-6) into phospholipid and triacylglycerol fractions. The increased incorporation of [1-(14)C]18:2(n-6) into phospholipid was attributed to significantly increased incorporation of [1-(14)C]18:2(n-6) into phosphatidylcholine and phosphatidylinositol. In CF cells expressing the defective DeltaF508 CFTR gene, conversion of [1-(14)C]18:2(n-6) to 20:4(n-6) by desaturation-chain elongation was 1.8-fold greater (P: < 0.05) than observed for CF cells transfected with the normal gene. The observations suggest that CF results in a defect in the utilization of 18:2(n-6), which is attributed in part to the defective CFTR.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11110839     DOI: 10.1093/jn/130.12.2870

Source DB:  PubMed          Journal:  J Nutr        ISSN: 0022-3166            Impact factor:   4.798


  17 in total

1.  Effect of Oral Lipid Matrix Supplement on Fat Absorption in Cystic Fibrosis: A Randomized Placebo-Controlled Trial.

Authors:  Virginia A Stallings; Joan I Schall; Asim Maqbool; Maria R Mascarenhas; Belal N Alshaikh; Kelly A Dougherty; Kevin Hommel; Jamie Ryan; Okan U Elci; Walter A Shaw
Journal:  J Pediatr Gastroenterol Nutr       Date:  2016-12       Impact factor: 2.839

2.  Low linoleic and high docosahexaenoic acids in a severe phenotype of transgenic cystic fibrosis mice.

Authors:  Birgitta Strandvik; Wanda K O Neal; Mohamed A Ali; Ulf Hammar
Journal:  Exp Biol Med (Maywood)       Date:  2018-03

3.  Linoleic acid supplementation results in increased arachidonic acid and eicosanoid production in CF airway cells and in cftr-/- transgenic mice.

Authors:  Munir M Zaman; Camilia R Martin; Charlotte Andersson; Abdul Q Bhutta; Joanne E Cluette-Brown; Michael Laposata; Steven D Freedman
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-07-23       Impact factor: 5.464

4.  Serum linoleic acid status as a clinical indicator of essential fatty acid status in children with cystic fibrosis.

Authors:  Asim Maqbool; Joan I Schall; J Felipe Garcia-Espana; Babette S Zemel; Birgitta Strandvik; Virginia A Stallings
Journal:  J Pediatr Gastroenterol Nutr       Date:  2008-11       Impact factor: 2.839

5.  Cystic fibrosis-related diabetes: from CFTR dysfunction to oxidative stress.

Authors:  Thierry Ntimbane; Blandine Comte; Geneviève Mailhot; Yves Berthiaume; Vincent Poitout; Marc Prentki; Rémi Rabasa-Lhoret; Emile Levy
Journal:  Clin Biochem Rev       Date:  2009-11

6.  CFTR depletion results in changes in fatty acid composition and promotes lipogenesis in intestinal Caco 2/15 cells.

Authors:  Geneviève Mailhot; Rémi Rabasa-Lhoret; Alain Moreau; Yves Berthiaume; Emile Levy
Journal:  PLoS One       Date:  2010-05-05       Impact factor: 3.240

7.  Cell culture models demonstrate that CFTR dysfunction leads to defective fatty acid composition and metabolism.

Authors:  Charlotte Andersson; M Rabie Al-Turkmani; Juanito E Savaille; Ragheed Alturkmani; Waddah Katrangi; Joanne E Cluette-Brown; Munir M Zaman; Michael Laposata; Steven D Freedman
Journal:  J Lipid Res       Date:  2008-04-25       Impact factor: 5.922

8.  A mechanism accounting for the low cellular level of linoleic acid in cystic fibrosis and its reversal by DHA.

Authors:  M Rabie Al-Turkmani; Charlotte Andersson; Ragheed Alturkmani; Waddah Katrangi; Joanne E Cluette-Brown; Steven D Freedman; Michael Laposata
Journal:  J Lipid Res       Date:  2008-05-14       Impact factor: 5.922

9.  Neutrophil generation of inflammatory precursors is not modulated by docosahexaenoic acid.

Authors:  Serena Quattrucci; Mariarosaria Napolitano; Sara Benedetti Valentini; Alessandro Giuliani; Elena Bravo
Journal:  Inflamm Res       Date:  2009-03-31       Impact factor: 4.575

10.  Preliminary evidence for cell membrane amelioration in children with cystic fibrosis by 5-MTHF and vitamin B12 supplementation: a single arm trial.

Authors:  Cinzia Scambi; Lucia De Franceschi; Patrizia Guarini; Fabio Poli; Angela Siciliano; Patrizia Pattini; Andrea Biondani; Valentina La Verde; Oscar Bortolami; Francesco Turrini; Franco Carta; Ciro D'Orazio; Baroukh M Assael; Giovanni Faccini; Lisa M Bambara
Journal:  PLoS One       Date:  2009-03-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.